{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T00:44:07Z","timestamp":1792629847004,"version":"4.5.0"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T00:00:00Z","timestamp":1784937600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T00:00:00Z","timestamp":1792627200000},"content-version":"vor","delay-in-days":89,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Takeda Pharmaceuticals U.S.A., Inc"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Gastroenterol"],"DOI":"10.1186\/s12876-026-04804-7","type":"journal-article","created":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T13:16:14Z","timestamp":1784985374000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Comparative efficacy and safety of subcutaneous vedolizumab versus other targeted inflammatory bowel therapies in patients with moderate to severe ulcerative colitis: a network meta-analysis update"],"prefix":"10.1186","volume":"26","author":[{"given":"Jeanne","family":"Jiang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abigail","family":"Wojtowicz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Uyei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"He","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristina","family":"Lindsley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie","family":"Sanchirico","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,25]]},"reference":[{"issue":"8","key":"4804_CR1","doi-asserted-by":"publisher","first-page":"2646","DOI":"10.3390\/jcm9082646","volume":"9","author":"V Solitano","year":"2020","unstructured":"Solitano V, D\u2019Amico F, Zacharopoulou E, et al. Early intervention in ulcerative colitis: Ready for prime time? J Clin Med. 2020;9(8):2646.","journal-title":"J Clin Med"},{"issue":"6","key":"4804_CR2","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1016\/j.cgh.2012.01.010","volume":"10","author":"T Jess","year":"2012","unstructured":"Jess T, Rungoe C, Peyrin-Biroulet L. Risk of colorectal cancer in patients with ulcerative colitis: A meta-analysis of population-based cohort studies. Clin Gastroenterol Hepatol. 2012;10(6):639\u201345.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"10","key":"4804_CR3","doi-asserted-by":"publisher","first-page":"2031","DOI":"10.1016\/j.cgh.2020.10.039","volume":"19","author":"L Tsai","year":"2021","unstructured":"Tsai L, Ma C, Dulai PS, et al. Contemporary risk of surgery in patients with ulcerative colitis and crohn\u2019s disease: A meta-analysis of population-based cohorts. Clin Gastroenterol Hepatol. 2021;19(10):2031\u201345.e11.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"9","key":"4804_CR4","doi-asserted-by":"publisher","first-page":"1324","DOI":"10.1038\/ajg.2015.233","volume":"110","author":"L Peyrin-Biroulet","year":"2015","unstructured":"Peyrin-Biroulet L, Sandborn W, Sands BE, et al. Selecting therapeutic targets in inflammatory bowel disease (STRIDE): Determining therapeutic goals for treat-to-target. Am J Gastroenterol. 2015;110(9):1324\u201338.","journal-title":"Am J Gastroenterol"},{"issue":"5","key":"4804_CR5","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1080\/1744666X.2022.2069562","volume":"18","author":"J Hanzel","year":"2022","unstructured":"Hanzel J, Hulshoff MS, Grootjans J, et al. Emerging therapies for ulcerative colitis. Expert Rev Clin Immunol. 2022;18(5):513\u201324.","journal-title":"Expert Rev Clin Immunol"},{"issue":"5","key":"4804_CR6","doi-asserted-by":"publisher","first-page":"1450","DOI":"10.1053\/j.gastro.2020.01.006","volume":"158","author":"JD Feuerstein","year":"2020","unstructured":"Feuerstein JD, Isaacs KL, Schneider Y, et al. AGA clinical practice guidelines on the management of moderate to severe ulcerative colitis. Gastroenterology. 2020;158(5):1450\u201361.","journal-title":"Gastroenterology"},{"issue":"4","key":"4804_CR7","doi-asserted-by":"publisher","first-page":"1156","DOI":"10.1053\/j.gastro.2021.06.015","volume":"161","author":"L Peyrin-Biroulet","year":"2021","unstructured":"Peyrin-Biroulet L, Loftus EV Jr., Colombel JF, et al. Histologic outcomes with vedolizumab versus adalimumab in ulcerative colitis: Results from an efficacy and safety study of vedolizumab intravenous compared to adalimumab subcutaneous in participants with ulcerative colitis (VARSITY). Gastroenterology. 2021;161(4):1156\u201367.e3.","journal-title":"Gastroenterology"},{"issue":"7","key":"4804_CR8","doi-asserted-by":"publisher","first-page":"1307","DOI":"10.1053\/j.gastro.2024.10.001","volume":"167","author":"S Singh","year":"2024","unstructured":"Singh S, Loftus EV Jr., Limketkai BN, et al. AGA living clinical practice guideline on pharmacological management of moderate-to-severe ulcerative colitis. Gastroenterology. 2024;167(7):1307\u201343.","journal-title":"Gastroenterology"},{"issue":"7","key":"4804_CR9","doi-asserted-by":"publisher","first-page":"1460","DOI":"10.1053\/j.gastro.2024.07.046","volume":"167","author":"AN Ananthakrishnan","year":"2024","unstructured":"Ananthakrishnan AN, Murad MH, Scott FI, et al. Comparative efficacy of advanced therapies for management of moderate-to-severe ulcerative colitis: 2024 American Gastroenterological Association evidence synthesis. Gastroenterology. 2024;167(7):1460\u201382.","journal-title":"Gastroenterology"},{"issue":"1","key":"4804_CR10","doi-asserted-by":"publisher","first-page":"943","DOI":"10.18549\/PharmPract.2017.01.943","volume":"15","author":"FS Tonin","year":"2017","unstructured":"Tonin FS, Rotta I, Mendes AM, et al. Network meta-analysis: A technique to gather evidence from direct and indirect comparisons. Pharm Pract (Granada). 2017;15(1):943.","journal-title":"Pharm Pract (Granada)"},{"issue":"2","key":"4804_CR11","doi-asserted-by":"publisher","first-page":"58","DOI":"10.3390\/jmahp12020006","volume":"12","author":"B Macabeo","year":"2024","unstructured":"Macabeo B, Quen\u00e9chdu A, Aball\u00e9a S, et al. Methods for indirect treatment comparison: Results from a systematic literature review. J Mark Access Health Policy. 2024;12(2):58\u201380.","journal-title":"J Mark Access Health Policy"},{"issue":"6","key":"4804_CR12","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1080\/17474124.2021.1880319","volume":"15","author":"V Jairath","year":"2021","unstructured":"Jairath V, Chan K, Lasch K, et al. Integrating efficacy and safety of vedolizumab compared with other advanced therapies to assess net clinical benefit of ulcerative colitis treatments: A network meta-analysis. Expert Rev Gastroenterol Hepatol. 2021;15(6):711\u201322.","journal-title":"Expert Rev Gastroenterol Hepatol"},{"issue":"10383","key":"4804_CR13","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1016\/S0140-6736(23)00061-2","volume":"401","author":"WJ Sandborn","year":"2023","unstructured":"Sandborn WJ, Vermeire S, Peyrin-Biroulet L, et al. Etrasimod as induction and maintenance therapy for ulcerative colitis (ELEVATE): Two randomised, double-blind, placebo-controlled, phase 3 studies. Lancet. 2023;401(10383):1159\u201371.","journal-title":"Lancet"},{"issue":"14","key":"4804_CR14","doi-asserted-by":"publisher","first-page":"1280","DOI":"10.1056\/NEJMoa2033617","volume":"385","author":"WJ Sandborn","year":"2021","unstructured":"Sandborn WJ, Feagan BG, D\u2019Haens G, et al. Ozanimod as induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2021;385(14):1280\u201391.","journal-title":"N Engl J Med"},{"issue":"8","key":"4804_CR15","doi-asserted-by":"publisher","first-page":"2139","DOI":"10.1053\/j.gastro.2020.02.030","volume":"158","author":"WJ Sandborn","year":"2020","unstructured":"Sandborn WJ, Ghosh S, Panes J, et al. Efficacy of upadacitinib in a randomized trial of patients with active ulcerative colitis. Gastroenterology. 2020;158(8):2139\u201349.e14.","journal-title":"Gastroenterology"},{"issue":"26","key":"4804_CR16","doi-asserted-by":"publisher","first-page":"2444","DOI":"10.1056\/NEJMoa2207940","volume":"388","author":"G D\u2019Haens","year":"2023","unstructured":"D\u2019Haens G, Dubinsky M, Kobayashi T, et al. Mirikizumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2023;388(26):2444\u201355.","journal-title":"N Engl J Med"},{"key":"4804_CR17","unstructured":"Pfizer. Velsipity\u2122 (etrasimod) prescribing information 2024 [Available from: https:\/\/labeling.pfizer.com\/ShowLabeling.aspx?id=19776 ]."},{"key":"4804_CR18","unstructured":"Bristol Myers Squibb. Zeposia\u00ae (ozanimod) prescribing information 2024 [Available from: https:\/\/packageinserts.bms.com\/pi\/pi_zeposia.pdf ]."},{"key":"4804_CR19","unstructured":"AbbVie. Rinvoq\u00ae (upadacitinib) prescribing information 2024 [Available from: https:\/\/www.rxabbvie.com\/pdf\/rinvoq_pi.pdf ]."},{"key":"4804_CR20","unstructured":"Lilly. Omvoh\u2122 (mirikizumab-mrkz) prescribing information 2024 [Available from: https:\/\/uspl.lilly.com\/omvoh\/omvoh.html#pi ]."},{"key":"4804_CR21","unstructured":"Takeda Pharmaceuticals USA, Inc. U.S. FDA approves subcutaneous administration of Takeda\u2019s ENTYVIO\u00ae (vedolizumab) for maintenance therapy in moderately to severely active ulcerative colitis 2023 [updated September 27, 2023. Available from: ] https:\/\/www.takeda.com\/newsroom\/newsreleases\/2023\/US-FDA-Approves-Subcutaneous-Administration-of-Takeda-ENTYVIO-vedolizumab-for-Maintenance-Therapy-in-Moderately-to-Severely-Active-Ulcerative-Colitis\/"},{"issue":"5","key":"4804_CR22","doi-asserted-by":"publisher","first-page":"1570","DOI":"10.1053\/j.gastro.2020.12.031","volume":"160","author":"D Turner","year":"2021","unstructured":"Turner D, Ricciuto A, Lewis A, et al. STRIDE-II: An update on the selecting therapeutic targets in inflammatory bowel disease (STRIDE) initiative of the International Organization for the Study of IBD (IOIBD): Determining therapeutic goals for treat-to-target strategies in IBD. Gastroenterology. 2021;160(5):1570\u201383.","journal-title":"Gastroenterology"},{"key":"4804_CR23","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/bmj.n71","volume":"372","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: An updated guideline for reporting systematic reviews. BMJ. 2021;372:n71.","journal-title":"BMJ"},{"issue":"Supplement1","key":"4804_CR24","doi-asserted-by":"publisher","first-page":"i574","DOI":"10.1093\/ecco-jcc\/jjac190.0575","volume":"17","author":"L Peyrin-Biroulet","year":"2023","unstructured":"Peyrin-Biroulet L, Bossuyt P, Bettenworth D, et al. P445 network meta-analysis to evaluate the comparative efficacy of intravenous and subcutaneous infliximab and vedolizumab in the maintenance treatment of adult patients with Crohn\u2019s disease and ulcerative colitis. J Crohns Colitis. 2023;17(Supplement1):i574\u20136.","journal-title":"J Crohns Colitis"},{"issue":"4","key":"4804_CR25","doi-asserted-by":"publisher","first-page":"370","DOI":"10.2174\/1389450121666201211162527","volume":"22","author":"L Loy","year":"2021","unstructured":"Loy L, Fiorino G, Roda G, et al. New paradigms to help decisions in treatment choice: Head to head trial of biological therapies in inflammatory bowel diseases. Curr Drug Targets. 2021;22(4):370\u20138.","journal-title":"Curr Drug Targets"},{"issue":"5","key":"4804_CR26","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1002\/art.41580","volume":"73","author":"M Yates","year":"2021","unstructured":"Yates M, Mootoo A, Adas M, et al. Venous thromboembolism risk with JAK inhibitors: A meta-analysis. Arthritis Rheumatol. 2021;73(5):779\u201388.","journal-title":"Arthritis Rheumatol"},{"issue":"1","key":"4804_CR27","doi-asserted-by":"publisher","first-page":"53","DOI":"10.5217\/ir.2019.09146","volume":"19","author":"T Hibi","year":"2021","unstructured":"Hibi T, Kamae I, Pinton P, et al. Efficacy of biologic therapies for biologic-na\u00efve Japanese patients with moderately to severely active ulcerative colitis: A network meta-analysis. Intest Res. 2021;19(1):53\u201361.","journal-title":"Intest Res"},{"issue":"Supplement1","key":"4804_CR28","doi-asserted-by":"publisher","first-page":"i623","DOI":"10.1093\/ecco-jcc\/jjac190.0622","volume":"17","author":"BE Sands","year":"2023","unstructured":"Sands BE, Hanauer SB, Colombel JF, et al. P492 subcutaneous infliximab (CT-P13 SC) as maintenance therapy for ulcerative colitis: A phase 3, randomized, placebo-controlled study: Results of the LIBERTY-UC study. J Crohns Colitis. 2023;17(Supplement1):i623\u20134.","journal-title":"J Crohns Colitis"},{"issue":"1","key":"4804_CR29","doi-asserted-by":"publisher","first-page":"otac044","DOI":"10.1093\/crocol\/otac044","volume":"5","author":"MC Dubinsky","year":"2022","unstructured":"Dubinsky MC, Clemow DB, Hunter Gibble T, et al. Clinical effect of mirikizumab treatment on bowel urgency in patients with moderately to severely active ulcerative colitis and the clinical relevance of bowel urgency improvement for disease remission. Crohns Colitis 360. 2022;5(1):otac044.","journal-title":"Crohns Colitis 360"},{"issue":"7","key":"4804_CR30","doi-asserted-by":"publisher","first-page":"1130","DOI":"10.1093\/ecco-jcc\/jjaa249","volume":"15","author":"S Vermeire","year":"2021","unstructured":"Vermeire S, Su C, Lawendy N, et al. Outcomes of tofacitinib dose reduction in patients with ulcerative colitis in stable remission from the randomised RIVETING trial. J Crohns Colitis. 2021;15(7):1130\u201341.","journal-title":"J Crohns Colitis"},{"issue":"7","key":"4804_CR31","doi-asserted-by":"publisher","first-page":"1891","DOI":"10.1053\/j.gastro.2022.02.033","volume":"162","author":"J Pan\u00e9s","year":"2022","unstructured":"Pan\u00e9s J, Colombel JF, D\u2019Haens GR, et al. Higher vs standard adalimumab induction and maintenance dosing regimens for treatment of ulcerative colitis: SERENE UC trial results. Gastroenterology. 2022;162(7):1891\u2013910.","journal-title":"Gastroenterology"},{"key":"4804_CR32","doi-asserted-by":"crossref","unstructured":"Vermeire S, Danese S, Zhou W, et al. OP23 efficacy and safety of upadacitinib as induction therapy in patients with moderately to severely active ulcerative colitis: Results from phase 3 U-ACCOMPLISH study. 2021;15(Suppl 1):S021\u20132.","DOI":"10.1093\/ecco-jcc\/jjab075.022"},{"key":"4804_CR33","unstructured":"ClinicalTrials.gov. Etrasimod versus placebo for the treatment of moderately to severely active ulcerative colitis (ELEVATE UC 52) [Available from: ] https:\/\/clinicaltrials.gov\/study\/NCT03945188"},{"key":"4804_CR34","unstructured":"ClinicalTrials.gov. A study of the efficacy and safety of upadacitinib (ABT-494) in participants with moderately to severely active ulcerative colitis (U-ACCOMPLISH) [Available from: ] https:\/\/clinicaltrials.gov\/study\/NCT03653026"},{"key":"4804_CR35","doi-asserted-by":"publisher","first-page":"l4898","DOI":"10.1136\/bmj.l4898","volume":"366","author":"JAC Sterne","year":"2019","unstructured":"Sterne JAC, Savovi\u0107 J, Page MJ, et al. RoB 2: A revised tool for assessing risk of bias in randomised trials. BMJ. 2019;366:l4898.","journal-title":"BMJ"},{"issue":"5","key":"4804_CR36","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1177\/0272989X12458724","volume":"33","author":"S Dias","year":"2013","unstructured":"Dias S, Sutton AJ, Ades AE, et al. Evidence synthesis for decision making 2: A generalized linear modeling framework for pairwise and network meta-analysis of randomized controlled trials. Med Decis Mak. 2013;33(5):607\u201317.","journal-title":"Med Decis Mak"},{"key":"4804_CR37","doi-asserted-by":"crossref","unstructured":"Burr NE, Gracie DJ, Black CJ, et al. Efficacy of biological therapies and small molecules in moderate to severe ulcerative colitis: systematic review and network meta-analysis. Gut. 2022;71(10):1976\u201387.","DOI":"10.1136\/gutjnl-2021-326390"},{"issue":"2","key":"4804_CR38","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/S2468-1253(21)00377-0","volume":"7","author":"JS Lasa","year":"2022","unstructured":"Lasa JS, Olivera PA, Danese S, et al. Efficacy and safety of biologics and small molecule drugs for patients with moderate-to-severe ulcerative colitis: A systematic review and network meta-analysis. Lancet Gastroenterol Hepatol. 2022;7(2):161\u201370.","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"10","key":"4804_CR39","doi-asserted-by":"publisher","first-page":"2179","DOI":"10.1016\/j.cgh.2020.01.008","volume":"18","author":"S Singh","year":"2020","unstructured":"Singh S, Murad MH, Fumery M, et al. First- and second-line pharmacotherapies for patients with moderate to severely active ulcerative colitis: An updated network meta-analysis. Clin Gastroenterol Hepatol. 2020;18(10):2179\u201391.e6.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"43","key":"4804_CR40","doi-asserted-by":"publisher","first-page":"e35689","DOI":"10.1097\/MD.0000000000035689","volume":"102","author":"J Gao","year":"2023","unstructured":"Gao J, Nie R, Chen Y, et al. Comparative of the effectiveness and safety of biological agents, small molecule drugs, and microbiome therapies in ulcerative colitis: Systematic review and network meta-analysis. Med (Baltim). 2023;102(43):e35689.","journal-title":"Med (Baltim)"},{"issue":"2","key":"4804_CR41","doi-asserted-by":"publisher","first-page":"otad009","DOI":"10.1093\/crocol\/otad009","volume":"5","author":"R Panaccione","year":"2023","unstructured":"Panaccione R, Collins EB, Melmed GY, et al. Efficacy and safety of advanced therapies for moderately to severely active ulcerative colitis at induction and maintenance: An indirect treatment comparison using Bayesian network meta-analysis. Crohns Colitis 360. 2023;5(2):otad009.","journal-title":"Crohns Colitis 360"},{"issue":"1","key":"4804_CR42","doi-asserted-by":"publisher","first-page":"otad076","DOI":"10.1093\/crocol\/otad076","volume":"6","author":"WJ Sandborn","year":"2024","unstructured":"Sandborn WJ, Sands BE, Uddin S, et al. Clinical trial design in ulcerative colitis: Interpreting evolving endpoints based on post hoc analyses of the vedolizumab phase 3 trials GEMINI 1 and VISIBLE 1. Crohns Colitis 360. 2024;6(1):otad076.","journal-title":"Crohns Colitis 360"},{"issue":"2","key":"4804_CR43","doi-asserted-by":"publisher","first-page":"otae038","DOI":"10.1093\/crocol\/otae038","volume":"6","author":"J Hanzel","year":"2024","unstructured":"Hanzel J, Ma C, Peyrin-Biroulet L, et al. Differences between the 2016 and 2022 Food and Drug Administration guidance-implications for design and interpretation of clinical trials in ulcerative colitis. Crohns Colitis 360. 2024;6(2):otae038.","journal-title":"Crohns Colitis 360"},{"key":"4804_CR44","doi-asserted-by":"publisher","first-page":"S647","DOI":"10.1016\/j.jval.2020.08.1466","volume":"23","author":"R Harvey","year":"2020","unstructured":"Harvey R, Charokopou M, Arteaga Duarte C, et al. Network meta-analysis: A comparison of Bayesian and frequentist approaches to synthesis, and evaluation of their suitability for decision-making. Value Health. 2020;23:S647.","journal-title":"Value Health"},{"issue":"38","key":"4804_CR45","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3310\/hta4380","volume":"4","author":"DJ Spiegelhalter","year":"2000","unstructured":"Spiegelhalter DJ, Myles JP, Jones DR, et al. Bayesian methods in health technology assessment: A review. Health Technol Assess. 2000;4(38):1\u2013130.","journal-title":"Health Technol Assess"}],"container-title":["BMC Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12876-026-04804-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12876-026-04804-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12876-026-04804-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T00:16:06Z","timestamp":1792628166000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12876-026-04804-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,25]]},"references-count":45,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4804"],"URL":"https:\/\/doi.org\/10.1186\/s12876-026-04804-7","relation":{},"ISSN":["1471-230X"],"issn-type":[{"value":"1471-230X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,25]]},"assertion":[{"value":"27 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable as this analysis used de-identified published clinical trial data.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Jeanne Jiang, Abigail Wojtowicz, and Marie Sanchirico are employees of Takeda Pharmaceuticals U.S.A., Inc. and hold stock or stock options. Jennifer Uyei, He Jin, and Kristina Lindsley are employees of IQVIA, which was paid by Takeda Pharmaceuticals U.S.A., Inc. to conduct this study.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"687"}}